CASE REPORTSAcute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patientPapadimitriou, George N.; Theleritis, Christos G.; Dikeos, Dimitris G.; Psarros, Constantin J.; Soldatos, Constantin R.Author Information Department of Psychiatry, Athens University Medical School, Eginition Hospital, Athens, Greece Correspondence and requests for reprints to George N. Papadimitriou, Department of Psychiatry, Athens University Medical School, Eginition Hospital, 74 Vas. Sofias Avenue, Athens 11528, Greece Tel: +30 210728 9324; e-mail: [email protected] Received 27 June 2005 Accepted 5 July 2005 International Clinical Psychopharmacology: May 2006 - Volume 21 - Issue 3 - p 181-184 doi: 10.1097/01.yic.0000182119.51672.f0 Buy Metrics Abstract The introduction of atypical antipsychotics into clinical practice has lead to an increase of adverse metabolic effects in psychotic patients. Amisulpride is a substituted benzamide derivative, and its use is associated with a lower risk of weight gain compared to other atypical antipsychotics. The case of an acute and excessive weight increase in a female first-episode schizophrenic patient who was treated with amisulpride monotherapy is reported. The improvement in psychopathology was remarkable. However, the patient gained 12.9 kg of body weight in the first 2 months of amisulpride administration and a total of 17.3 kg, 6 months after initiation of the treatment. Glucose and insulin levels, as well as a glucose tolerance test, remained normal throughout the observation period. © 2006 Lippincott Williams & Wilkins, Inc.